Tirzepatide

Where the papers sit

40 papers from the last 6 months study tirzepatide directly · updated from PubMed 12 Oct 2026

• Diabetes and Cardiometabolic Outcomes

  Glycemic control, weight reduction and cardiometabolic risk are the main targets across type 1 and type 2 diabetes. Real-world studies extend use into overweight or obese people with type 1 diabetes and Japanese patients without obesity, while comparisons with semaglutide, dulaglutide and bariatric surgery assess treatment value. Liver fat, major adverse liver outcomes, kidney events and atherosclerotic cardiovascular events recur as secondary endpoints. Broader use is accompanied by surveillance for rare harms such as pneumatosis intestinalis and pregnancy-related uncertainty.

  14 papers · 35%

• GLP-1 Therapy Beyond Glycemia

  GLP-1 and GIP/GLP-1 agonists are being evaluated beyond routine glucose lowering, especially for obesity, recurrent post-bariatric weight gain and treatment intensification. Real-world work focuses on persistence, background medication changes, adverse events, financing and comparisons with bariatric surgery. Candidate benefits in alcohol-related hospitalisation and toxic amyloid-β42 aggregation remain exploratory, with a mouse Alzheimer’s model showing no disease modification. Drug discovery is moving toward balanced, high-potency GLP-1/GIP agonists, but clinical breadth still exceeds firm evidence.

  12 papers · 30%

• Real-World Obesity Treatment

  Weight loss treatment is shifting from trial efficacy toward persistence, tolerability, access and patient-reported value in routine obesity care. Low-to-moderate doses are being tested against standard dosing, while digital services and peer referral pathways assess delivery and six-month outcomes. Waist-to-height ratio, blood pressure and non-HDL cholesterol broaden success beyond body weight alone. Cold exposure does not enhance tirzepatide-associated weight loss in mice, leaving combination strategies unresolved.

  7 papers · 17.5%

• Cardiovascular-Kidney-Metabolic Disease

  Cardiovascular-kidney-metabolic disease is being treated as an integrated syndrome in which liver dysfunction and steatohepatitis influence risk across organs. Tirzepatide is compared with other GLP-1 receptor agonists for progression through cardiometabolic stages using real-world outcomes. Metabolic dysfunction-associated steatohepatitis with significant fibrosis adds a liver-focused treatment and cost-effectiveness question. The literature is moving toward organ-integrated risk assessment rather than isolated diabetes endpoints.

  3 papers · 7.5%

• Others — Tirzepatide Safety and Pleiotropy

  Safety and broader biological effects are the only loose links across these reports. They include patient-reported outcomes with concurrent biologic therapy in psoriatic arthritis, possible thyroid risks, impurities in compounded tirzepatide/B12 products and anti-inflammatory neuroprotection in an Alzheimer’s model. The evidence spans clinical associations, product-quality surveillance and preclinical mechanisms rather than one disease program. No consistent therapeutic direction or shared endpoint emerges.

  4 papers · 10%